Fixed-Dose Combination of Tafluprost and Timolol in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: Comparison with Other Fixed-Combination Products

Gábor Holló, Jouni Vuorinen, Juhani Tuominen, Teppo Huttunen, Auli Ropo, Norbert Pfeiffer

Research output: Contribution to journalReview article

19 Citations (Scopus)


A new preservative-free fixed-dose combination of 0.0015% tafluprost, a prostaglandin F analog, and 0.5% timolol (TAF/TIM; Santen Oy, Tampere, Finland), a beta-adrenergic antagonist has recently been developed. The intraocular pressure (IOP) reduction with TAF/TIM in open-angle glaucoma and ocular hypertension is similar to that of other prostaglandin–timolol fixed-combination products. Patients with high IOP responded well to TAF/TIM with reductions of up to 40% (>13 mmHg) and beyond. Compared to previous controlled and double-masked clinical trials with DuoTrav® (Alcon, Fort Worth, USA) and Ganfort® (Allergan, Irvine, USA), TAF/TIM caused less superficial ocular side effects and less conjunctival hyperemia. Plausible explanations for the differences in side effects between the fixed-combination products are discussed.

Original languageEnglish
Pages (from-to)932-944
Number of pages13
JournalAdvances in Therapy
Issue number9
Publication statusPublished - Sep 27 2014



  • DuoTrav
  • Fixed-dose combination
  • Ganfort
  • Hyperemia
  • Intraocular pressure
  • Ophthalmology
  • Preservative free
  • Side effects
  • Tafluprost
  • Timolol
  • Xalacom

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this